Share this article
Share this article
LONDON, Feb. 23, 2021 /PRNewswire/ More than half (53%) of responding business tax leaders expect greater tax enforcement in the next three years, particularly as governments look to remedy budget pressures and stimulate their economies during the COVID-19 pandemic, according to the 2021 EY Tax Risk and Controversy Survey. EY teams canvassed the views of 1,265 tax and finance leaders across 60 jurisdictions and 20 industry sectors during the fourth quarter of 2020, making it the largest sample in the survey s history.
Business tax leader respondents highlighted issues around workers stranded overseas, treatment of financial losses linked to the pandemic, the claiming of tax refunds and even the receipt of stimulus measures as top pandemic-related tax risks. Respondents are also concerned about tax risk related to transfer pricing – skewed by the pandemic – and an acceleration in the digital transformation of tax authorities. Survey res
Scientists find new therapeutic approach to effectively treat age-related macular degeneration
Runt-related transcription factor 1 (RUNX1) has been linked to retinal neovascularization and the development of abnormal blood vessels, which result in vision loss in diabetic retinopathy. Now, scientists have found that RUNX1 inhibition presents a new therapeutic approach in the treatment of age-related macular degeneration (AMD), which is the leading cause of blindness in the elderly worldwide. Their results are reported in
The American Journal of Pathology, published by Elsevier.
Abnormal growth of blood vessels, or aberrant angiogenesis, arises from the choroid, a part of the eye located behind the retina. This condition, known as choroidal neovascularization (CNV), is present in several ocular diseases that lead to blindness such as AMD. This study is the first to implicate RUNX1 in CNV and to test RUNX1 inhibition therapy for treating CNV. Researchers found that application of a
(1)
LONDON, Feb. 23, 2021 (GLOBE NEWSWIRE) OKYO Pharma Limited ( OKYO or the Company ), a biotechnology company focused on the development of novel drugs to treat inflammatory eye diseases and chronic ocular pain, today announced that patent No. 10,899,796 entitled Compounds and Methods for Treating Pain was issued by the United States Patent and Trademark Office ( USPTO ) on January 26, 2021. This patent covers a class of bovine adrenal medulla (BAM) peptides linked to specific lipids that demonstrate potential for treating symptoms of neuropathic pain, ocular pain, ocular inflammation and/or dry eye disease.
The work recited in this patent lays out the potential of this class of lipidated BAM analogues as non-opioid analgesics for ocular pain management without the side effects and potential abuse associated with opioid medications. The Company originally announced in February 2018 that it had obtained exclusive licenses from On Target Therapeutics LLC and Tufts Medical C
The daily readings are taken from the lectionary which divides much of the Bible into three years worth of readings. If you complete the daily readings each day for three years, you will read 15 percent of the Old Testament and 71 percent of the New Testament.
Governments around the world are confronting budget deficits due to the COVID-19 pandemic and corporate tax leaders are worried about higher tax assessments, double taxation, penalties, interest and surcharges.